AU2005284565A1 - Combination of polychitosamine and HMG-CoA reductase inhibitor for hyperlipidemia - Google Patents

Combination of polychitosamine and HMG-CoA reductase inhibitor for hyperlipidemia Download PDF

Info

Publication number
AU2005284565A1
AU2005284565A1 AU2005284565A AU2005284565A AU2005284565A1 AU 2005284565 A1 AU2005284565 A1 AU 2005284565A1 AU 2005284565 A AU2005284565 A AU 2005284565A AU 2005284565 A AU2005284565 A AU 2005284565A AU 2005284565 A1 AU2005284565 A1 AU 2005284565A1
Authority
AU
Australia
Prior art keywords
hmg
reductase inhibitor
polychitosamine
coa reductase
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005284565A
Other languages
English (en)
Inventor
Andre Aube
Ryszard Brzezinski
Gilles Dupuis
Jean-Francois Huc
Jean-Guy Lehoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DNP Canada Inc
Original Assignee
DNP Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DNP Canada Inc filed Critical DNP Canada Inc
Publication of AU2005284565A1 publication Critical patent/AU2005284565A1/en
Assigned to DNP CANADA INC. reassignment DNP CANADA INC. Request for Assignment Assignors: Magistral Biotech Inc., Has no value - Entry Incomplete
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Stereo-Broadcasting Methods (AREA)
AU2005284565A 2004-09-15 2005-09-14 Combination of polychitosamine and HMG-CoA reductase inhibitor for hyperlipidemia Abandoned AU2005284565A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60983004P 2004-09-15 2004-09-15
US60/609,830 2004-09-15
PCT/CA2005/001406 WO2006029524A1 (en) 2004-09-15 2005-09-14 Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia

Publications (1)

Publication Number Publication Date
AU2005284565A1 true AU2005284565A1 (en) 2006-03-23

Family

ID=36059676

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005284565A Abandoned AU2005284565A1 (en) 2004-09-15 2005-09-14 Combination of polychitosamine and HMG-CoA reductase inhibitor for hyperlipidemia

Country Status (8)

Country Link
US (5) US20060058261A1 (enExample)
EP (1) EP1812019A4 (enExample)
JP (1) JP2008513379A (enExample)
CN (1) CN101052405A (enExample)
AU (1) AU2005284565A1 (enExample)
BR (1) BRPI0515443A (enExample)
CA (1) CA2580460A1 (enExample)
WO (1) WO2006029524A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
US9078849B2 (en) 2009-04-08 2015-07-14 Nanyang Polytechnic Plant extract comprising statins and preparation techniques and uses thereof
CA2869821C (en) 2011-06-13 2018-06-19 Rival, Societe En Commandite N,n,n-trialkylaminopolymers, methods of their preparation and uses thereof
EP3856626B1 (en) * 2018-09-26 2024-05-15 TQ-Systems GmbH Method and device for dynamically controlling a range of an electrically-assisted bicycle, electrically-assisted bicycle
IT201900021291A1 (it) * 2019-11-15 2021-05-15 Biomedica Pharma Gmbh Chitosano e prodotto medicale per l’uso in un metodo di prevenzione o trattamento di una malattia cardiovascolare

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903140A (en) * 1970-09-08 1975-09-02 Alza Corp Diazadodecane prostaglandin compounds
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2146549C (en) * 1992-12-01 2005-01-04 Karl F. Roenigk Durable antimicrobial agents
FI107432B (fi) * 1997-02-06 2001-08-15 Novasso Oy Mikrokiteisen kitosaanin käyttö
FI982291L (fi) * 1998-10-23 2000-04-24 Novasso Oy Aine kolesterolin sekä lipidien pitoisuuden alentamiseksi
US20020016307A1 (en) * 1999-10-27 2002-02-07 Mullins John Jason Gentry Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity
US6933291B2 (en) * 2000-12-01 2005-08-23 N.V. Nutricia Cholesterol lowering supplement
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition

Also Published As

Publication number Publication date
US20090197830A1 (en) 2009-08-06
WO2006029524A1 (en) 2006-03-23
CA2580460A1 (en) 2006-03-23
US20130244973A1 (en) 2013-09-19
EP1812019A1 (en) 2007-08-01
US20110028429A1 (en) 2011-02-03
BRPI0515443A (pt) 2008-07-29
JP2008513379A (ja) 2008-05-01
US20060058261A1 (en) 2006-03-16
CN101052405A (zh) 2007-10-10
EP1812019A4 (en) 2007-12-26
US20120258932A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
US20120258932A1 (en) Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia
CN1104897C (zh) 作为3－羟基－3－甲基戊二酰基CoA(HMG－CoA)还原酶抑制剂的橙皮苷和橙皮素
JP2005514342A (ja) 栄養補助作用および栄養強化作用を有する薬用−食調製物
US20100048507A1 (en) Food/beverage and pharmaceutical composition for oral administration for improvement in acidic urine each comprising fucoidan as active ingredient
JP2003155244A (ja) モズク由来のフコイダンを含む食品
US20090054373A1 (en) Chitin derivatives for hyperlipidemia
JP3634721B2 (ja) 高脂血症の予防又は治療剤
US20080293671A1 (en) Combination of Polychitosamine and Fibrate for the Prevention and Treatment of Hyperlipidemia
US8613963B2 (en) Nutritional supplement
HK1114007A (en) Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia
HK1126389A (en) Combination of polychitosamine and fibrate for the prevention and treatment of hyperlipidemia
AU7667501A (en) Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms
CN1953670B (zh) 组合物、组合物的用途以及治疗肥胖症的方法
US20080305095A1 (en) Nutritional Drink
JP2011241216A (ja) モズク由来のフコイダンを含む食品
US20100021572A1 (en) Nutritional Drink
CN116570600B (zh) 协同抑制乙酰胆碱酯酶的加兰他敏组合物
CA2717159A1 (en) Nutritional supplement
HK1022104B (en) Hesperidin and hesperetin as 3-hydroxy-3-methylglutaryl coa(hmg-coa) reductase inhibitor
CA2717157A1 (en) Nutritional drink
MXPA99011665A (en) Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DNP CANADA INC.

Free format text: FORMER APPLICANT(S): MAGISTRAL BIOTECH INC., HAS NO VALUE - ENTRY INCOMPLETE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE CO-INVENTOR NAME TO READ HUC, JEAN-FRANCOIS

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application